

## News Releases

All Years

Search

Go

[Advanced Search](#)

**NOV 4, 2025**

**Inhibrx Announces Participation in Upcoming Scientific Conferences**

**OCT 23, 2025**

**Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts**

**OCT 22, 2025**

**Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts**

**AUG 13, 2025**

**Inhibrx Reports Second Quarter 2025 Financial Results**

**MAY 14, 2025**

**Inhibrx Reports First Quarter 2025 Financial Results**

**APR 1, 2025**

**Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President**

**MAR 17, 2025**

## **Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results**

**JAN 21, 2025**

## **Inhibrx Biosciences Announces Preliminary Data from the Phase 1 Trial of ozekibart (INBRX-109) for the Treatment of Colorectal Cancer**

**JAN 13, 2025**

## **Inhibrx Biosciences Announces Loan Agreement with Oxford Finance**

**NOV 14, 2024**

## **Inhibrx Biosciences Reports Third Quarter 2024 Financial Results**

Show  per page

[«](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [»](#)



<https://inhibrx.investorroom.com/news-releases?l=10&o=10>